Comparison of cardiovascular events in two treatment groups
Initiated with PCSK-9 inhibitor combined with statins significantly reduce the incidence of cardiovascular events versus statins treatment (incidence 2.07% vs 8.29%, hazard ratio, 0.24, 95% CI, 0.12-0.51, P<0.0001) (Figure 2). The results showed lower risk of re-hospitalization (adjusted HR, 0.09; 95%CI, 0.03-0.31;P <0.001, figure 3), but there’re no difference in TVR, MI and re-angina between two groups. All prognostic subgroups received benefit from the PCSK-9 inhibitor combined statin treatment, while male patients treated by PCSK-9 inhibitor had a lower risk of cardiovascular events than those treated by statin w/wo other lipid lowering therapies (Figure 4).